Literature DB >> 8107950

Verotoxin-binding in human renal sections.

C A Lingwood1.   

Abstract

Gastrointestinal infection with verotoxin-producing Escherichia coli (VTEC) has been strongly implicated in the etiology of the hemolytic uremic syndrome (HUS), the leading cause of pediatric acute renal failure. The binding of fluorescein-conjugated VT1 overlaid on to frozen human renal sections has been examined. Sections from biopsies of infants aged < 2 years were compared with those from adult autopsies. VT primarily stained distal convoluted tubules, particularly those adjacent to glomeruli, and collecting ducts. VT-binding was detected within the infant glomerulus but not the adult. Binding of the toxin was removed when the section was pretreated with alpha-galactosidase, confirming the receptor-binding specificity for globotriaosyl ceramide (gal alpha 1-4gal beta 1-4 glucosylceramide), the glycolipid receptor for VT. These studies may suggest that differential localization of this glycolipid in the pediatric renal glomerulus is a risk factor for the development of HUS following infection with VTEC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107950     DOI: 10.1159/000187761

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  54 in total

1.  Effects of Shiga toxin 2 on lethality, fetuses, delivery, and puerperal behavior in pregnant mice.

Authors:  K Yoshimura; J Fujii; A Tanimoto; T Yutsudo; M Kashimura; S Yoshida
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Localization of potential binding sites for the edema disease verotoxin (VT2e) in pigs.

Authors:  T E Waddell; B L Coomber; C L Gyles
Journal:  Can J Vet Res       Date:  1998-04       Impact factor: 1.310

3.  Relationship between susceptibility to hemolytic-uremic syndrome and levels of globotriaosylceramide in human sera.

Authors:  S Watarai; K Yokota; T Kishimoto; T Kanadani; K Taketa; K Oguma
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

Review 4.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  Shigatoxin-1 binding and receptor expression in human kidneys do not change with age.

Authors:  Zuhal Ergonul; Frederic Clayton; Agnes B Fogo; Donald E Kohan
Journal:  Pediatr Nephrol       Date:  2003-02-07       Impact factor: 3.714

6.  Interaction of the verotoxin 1B subunit with soluble aminodeoxy analogues of globotriaosyl ceramides.

Authors:  Murugesapillai Mylvaganam; Henrik C Hansen; Beth Binnington; Göran Magnusson; Per-Georg Nyholm; Clifford A Lingwood
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

7.  Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Authors:  Richard L Siegler; Tom G Obrig; Theodore J Pysher; Vernon L Tesh; Nathaniel D Denkers; Fletcher B Taylor
Journal:  Pediatr Nephrol       Date:  2003-01-10       Impact factor: 3.714

8.  Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice.

Authors:  D Paixão-Cavalcante; M Botto; H T Cook; M C Pickering
Journal:  Clin Exp Immunol       Date:  2009-02       Impact factor: 4.330

Review 9.  Chronic sequelae of foodborne disease.

Authors:  J A Lindsay
Journal:  Emerg Infect Dis       Date:  1997 Oct-Dec       Impact factor: 6.883

10.  Epigallocatechin-3-gallate suppresses galactose-alpha1,4-galactose-1beta,4-glucose ceramide expression in TNF-alpha stimulated human intestinal epithelial cells through inhibition of MAPKs and NF-kappaB.

Authors:  Dong-Oh Moon; Se-Rim Choi; Chang-Min Lee; Gi-Young Kim; Hee-Jeong Lee; Yeong-Min Park
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.